Clinical Trial Finder

Inclusion criteria.

• - Patient must have histologically or cytologically confirmed advanced and/or metastatic solid tumor malignancies for which standard curative or palliative measures do not exist, are no longer effective, or are not acceptable to the patient.

• - Eastern Cooperative Oncology Group Performance Status 0-1.

• - Fresh biopsies may be required.

• - Women of childbearing potential and male participants must agree to remain abstinent or use contraceptive methods as defined by the protocol.

Additional Specific Inclusion Criteria for Participants with Melanoma.

• - Histologically confirmed, unresectable stage III or stage IV melanoma.

• - Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study.

• - Prior treatment with an approved anti-PD-1 or anti-PD-L1 agent.

Additional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease.

• - Participants with histologically confirmed advanced non-small cell lung cancer.

• - Not more than 2 prior lines of treatment for metastatic disease are allowed prior to enrolling in the study.

• - Previously treated with approved PD-L1/PD-1 inhibitors.

• - Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening.

Additional Specific Inclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma.

• - Participants whose major lesion was histologically confirmed as squamous cell carcinoma or adenosquamous cell carcinoma of the esophagus.

• - Participants who have previously received not more than 1 prior line of treatment for metastatic disease prior to enrolling in the study.

Additional Specific Inclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease.

• - Participants with histologically confirmed advanced non-small cell lung cancer.

• - Tumor PD-L1 expression as determined by immunohistochemistry assay of archival tumor tissue or tissue obtained at screening.

Exclusion criteria.

• - Pregnancy, lactation, or breastfeeding.

• - Known hypersensitivity to any of the components of RO7247669.

• - Active or untreated central nervous system (CNS) metastases.

• - An active second malignancy.

• - Evidence of concomitant diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participant at high risk from treatment complications.

• - Positive HIV, hepatitis B, or hepatitis C test result.

• - Known active or uncontrolled bacterial, viral, fungal, mycobacterial, parasitic, or other infection.

• - Vaccination with live vaccines within 28 days prior to Cycle 1 Day 1.

• - Treatment with oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1.

• - Active or history of autoimmune disease or immune deficiency.

• - Prior treatment with adoptive cell therapies, such as CAR-T therapies.

• - Concurrent therapy with any other investigational drug < 28 days or 5 half-lives of the drug, whichever is shorter, prior to the first RO7247669 administration.

• - Regular immunosuppressive therapy.

• - Radiotherapy within the last 4 weeks before start of study drug treatment, with the exception of limited palliative radiotherapy.

• - Prior treatment with a lymphocyte activation gene-3 (LAG-3) inhibitor.

Additional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously Received Treatment for Metastatic Disease.

• - Participants with the following muations, rearrangements, translocations are not eligible: EGFR, ALK, ROS1, BRAFV600E, and NTRK.

Additional Specific Exclusion Criteria for Participants with Esophageal Squamous Cell Carcinoma.

• - Prior therapy with any immunomodulatory agents.

Additional Specific Exclusion Criteria for Participants with Non-Small Cell Lung Cancer who Previously did not Receive Treatment for Metastatic Disease.

• - Prior therapy for metastatic disease is not permitted.

- Neo-adjuvant anti-PD-1 or anti-PD-L1 therapy is not allowed

Arms

Experimental: Part A: Single-Agent Dose Escalation

Participants will receive RO7247669 every 2 weeks (Q2W) or every 3 weeks (Q3W) up to the maximum tolerated dose (MTD) until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.

Experimental: Part B: Tumor Specific Expansion Cohorts

Participants with selected solid tumor indications will receive RO7247669 at a dose derived from Part A until disease progression, unacceptable drug toxicity, or withdrawal of consent, for up to 24 months.

Interventions

Drug: - RO7247669

Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)